Brief: Herantis Pharma Updates On Non-Invasive Next Generation CDNF (xCDNF) Development

Herantis Pharma Oyj

30/12/2019 09:07

Dec 30 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * HERANTIS PHARMA PLC PROVIDES UPDATE ON NON-INVASIVE NEXT
GENERATION CDNF (XCDNF) DEVELOPMENT
    * HERANTIS PHARMA OYJ - HAS NOW SELECTED A TOTAL OF THREE
LEAD
MOLECULES, WHICH IT INTENDS TO CARRY FORWARD IN ITS XCDNF
DEVELOPMENT
    * HERANTIS PHARMA OYJ - WE EXPECT INITIAL READ-OUTS FROM
THIS
FIRST-IN-HUMAN STUDY IN Q1/2020
    * HERANTIS PHARMA OYJ - THOUGH STILL IN EARLY STAGE OF
DEVELOPMENT, PROPERTIES OF OUR XCDNF LEAD CANDIDATES SUGGEST
POTENTIAL FOR DRUG DEVELOPMENT EVEN BEYOND PARKINSON'S DISEASE

Source text for Eikon:  ID:nWkr1dlH3S 
Further company coverage:  HRTIS.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))